SonoThera to Present Preclinical Data on Ultrasound-Mediated Gene Delivery Platform to the Heart at the American Heart Association (AHA) Scientific Sessions 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2024
0mins
Source: Businesswire
SonoThera's Presentation at AHA: SonoThera will present late-breaking data on its ultrasound-mediated nonviral gene therapy platform for cardiovascular disease at the American Heart Association Scientific Sessions from November 15-18, 2024, focusing on gene delivery to the heart in mice and macaques.
Innovative Gene Therapy Approach: The company aims to address delivery challenges in gene therapy by utilizing a non-invasive method that targets various organs with high safety and precision, showcasing their commitment to developing effective genetic medicines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
